We are the first commercial providers of a Causal AI technology that is capable of in silico exploration of biological pathway and mechanisms.   For this, we have built a first-of-a-kind software platform, ALaSCA.  

 

To date, ALaSCA has been used to discover and simulate the effect of drivers in a number of disease and treatment types - including Glioblastoma, Alzheimer's Disease, Chronic Liver Disease, Rare Kidney Disease,  Diabetes, AMR, and Bioactives.  

​

We are a global multi-disciplinary team consisting of 20 biologists, software engineers, mathematicians, advisors, sales & marketing; registered in The Netherlands with our HQ in the UK.

​

The team has decades of industry deal making and building businesses.  For example, taking IBM Watson Genomics to market in the US.

​

We have a strong Scientific Advisory Board – with leaders in the industry across Europe and the US.  For example, leading drug discovery programs at Roche and Eli Lilly.

 

To learn more about who we are, please reach out to Dr Raminderpal Singh via LinkedIn or at raminderpal@incubate.bio.